Phase II evaluation of copanlisib, a selective inhibitor of Pi3kca, in patients with persistent or recurrent endometrial carcinoma harboring PIK3CA hotspot mutations: An NRG Oncology study (NRG-GY008)

• 主要な著者: Alessandro D. Santin (著者), Virginia Filiaci (著者), Stefania Bellone (著者), Elena S. Ratner (著者), Cara A. Mathews (著者), Guilherme Cantuaria (著者), Camille C. Gunderson (著者), Teresa Rutledge (著者), Barbara M. Buttin (著者), Heather A. Lankes (著者), Michael Frumovitz (著者), Samir N. Khleif (著者), Warner K. Huh (著者), Michael J. Birrer (著者)
• フォーマット: 図書
• 出版事項: Elsevier, 2020-02-01T00:00:00Z.
• 主題: article
• オンライン･アクセス: Connect to this object online.

Purpose: NRG Oncology conducted a phase II trial to assess the antitumor activity and tolerability of copanlisib, a selective inhibitor of PIK3CA, in persistent or recurrent endometrial carcinoma harboring hotspot PIK3CA mutations. Patients and methods: Eligible patients had endometrial cancer with...